Change Registration: Substantial-Change Criteria and Dossier Composition

1. Key takeaways

China provides two channels for change and no third. The difficulty is not whether to notify but which channel applies, and a wrong choice cannot be corrected without losing the filing deadline.

• Only two statutory channels exist. Article 21 of the Regulations requires variation registration for a substantive change to a registered product, and filing or reporting for other changes.
• The filing channel carries a deadline. Article 79 requires other changes to be filed with the original registering authority within 30 days; variation registration has no equivalent start date, but the change may not be implemented before approval.
• Holder name and domicile, and agent name and domicile, are filing items and do not enter variation registration (Article 79). This is the most frequent misjudgement.
• Variation fees are tiered: domestic Class III CNY 50,400, import Class II CNY 42,000, import Class III CNY 50,400 (article 35).
• The dossier follows an incremental principle: submit the change and its supporting evidence rather than the entire first-registration file. Format follows NMPA Announcement No. 121 of 2021.
• Compliance must bridge the change: nothing may be produced or sold in the changed state before approval, and the technical requirements, instructions, labels and UDI data must be updated afterwards.
• Technical requirements are the most sensitive item. They form an annex to the certificate, so any adjustment follows the relevant procedure, and reviewed instructions may not be altered at will (Order No. 6, Article 16).

In our assessment, the cost of classifying a change is far below the cost of misclassifying it, since the wrong channel means repeating the procedure with the 30-day filing window already gone. The decision belongs in internal change control, not in the registration team’s after-the-fact handling.

2. Legal basis

Medical Device Supervision and Administration Regulations (State Council Order No. 739, promulgated 9 February 2021, effective 1 June 2021)

• Article 21: a substantive change to a registered product requires variation registration; other changes are filed or reported as prescribed.
• Article 39: instructions and labels shall meet the requirements of the Regulations and be consistent with the registered or filed content.

Medical Device Registration and Filing Measures (SAMR Order No. 47, promulgated 26 August 2021, effective 1 October 2021)

• Article 22: NMPA operates a registration communication mechanism.
• Article 26: requirements for drafting and content of product technical requirements.
• Article 32: an applicant may submit a self-test report or a report from a qualified testing institution.
• Article 79: a substantive change to a matter stated on the certificate requires variation registration; other changes must be filed within 30 days; holder name and domicile and agent name and domicile are filing items.

Provisions on the Administration of Medical Device Instructions and Labels (former CFDA Order No. 6, promulgated 30 July 2014, effective 1 October 2014)

• Article 4: content shall be scientific, truthful, complete and accurate, and consistent with the registered or filed content.
• Article 9: the text shall be in Chinese.
• Article 16: reviewed instructions may not be altered without authorisation.

Announcement No. 121 of 2021 (published 29 September 2021, effective 1 January 2022) sets the dossier requirements and approval document formats, including those for variation applications. Article 15 of the Unique Device Identification System Rules (NMPA, 2019) requires identifiers and related data to be uploaded before marketing.

Practical estimate. No itemised checklist of substantive change exists. Practice asks whether it affects safety or effectiveness, alters the approved technical boundary, or needs new evidence; any yes means variation registration, with the departments deciding.

Practical estimate. Certificate particulars whose change needs assessment usually include name, models, structure, intended use, technical requirements, principal materials, critical processes, sterilisation, shelf life, software version and algorithm, and manufacturing address. The list reflects practice and yields to the certificate and the department.

3. Expert insights

The boundary between the channels is a decision chain, not a list.

The third step matters most: Article 79 lists agent name and domicile alongside holder name and domicile as filing items, so appearing on the certificate does not make them a variation. For imports this arises constantly, since changing the Chinese agent needs a filing.

Three questions filter substantive change. The rules give no list, so practice tests each item.

The questions are layered: risk, consistency with what was approved, and evidence. One yes is enough. The recurring misjudgement is the improvement: engineering treats a performance gain as optimisation and never opens the procedure, yet the improvement also moves the approved technical boundary.

The incremental principle is not a full resubmission. Under the Announcement No. 121 format, a variation is organised around the change itself in four layers.

The evidence layer sets the timeline: a change needing new non-clinical work or clinical evaluation takes far longer than document updates.

Three steps cannot be skipped in the transition. First, nothing is implemented before approval, which is the timing difference between variation registration as ex-ante approval and filing as ex-post confirmation. Second, documents move together: technical requirements are an annex to the certificate and must be reissued, while instructions and labels must match the registered content under Articles 4 and 16. Third, UDI data must be reconciled where identifier attributes change, under Article 15. The third is most often missed, because registration addresses the product while the UDI database addresses identifier data.

4. Practical recommendations

• Move the decision into engineering change review. Add a registration impact step producing a written conclusion of variation, filing, report or no impact.
• Keep a register of certificate particulars, listing name, models, structure, intended use, technical requirements and manufacturing address, each mapped to its channel.
• Manage holder and agent details separately. Both are filing items under Article 79, so keep them out of the variation ledger with a 30-day alert.
• Build the dossier in the four layers, starting the evidence layer early so it does not become the critical path.
• Lock production and sales before approval. Add approval to the change release checklist and keep the original status until it is obtained.
• Update instructions and labels together, checking Chinese text and the smallest sales unit label against the registered content (Order No. 6, Articles 4 and 9).

5. Verification checklist

• □ The channel is determined as variation, filing or report, with the conclusion archived in writing.
• □ The three questions were applied: safety and effectiveness, technical boundary, new evidence.
• □ Agent and holder name and domicile changes were identified as filing items, not routed to variation registration.
• □ Filing-type changes were submitted within 30 days of the change.
• □ The dossier follows the Announcement No. 121 format on an incremental basis.
• □ A comparison table locates the change points.
• □ The evidence layer is complete: affected studies, test reports, clinical evaluation where relevant.
• □ Technical requirements were reissued and match the certificate annex (Article 26).
• □ Instruction and label drafts are updated in Chinese and consistent with the registered content (Order No. 6, Articles 4, 9 and 16).
• □ UDI data was checked and updated before marketing (System Rules, Article 15).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Chinese market. Our team acts as the in-China registration agent, coordinates import agent and distributor arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com